Drug Search Results
More Filters [+]

SNUG-01

Alternative Names: SNUG-01, SNUG 01, SNUG01
Latest Update: None
Latest Update Note: None

Product Description

SNUG01 is a gene therapy drug with adeno-associated virus (AAV) as the carrier, using Shenji Changhua's exclusive therapeutic target SG001, in order to achieve the therapeutic effect of "one-time administration, long-term effect.SNUG01 in preclinical animal experiments, showing a significant protective effect on neurons.SNUG01 is expected to open a new field of ALS treatment, improve the situation of no cure, and bring new hope to patients and their families. (Sourced from: https://www.jialabtsinghua.com/newsinfo/6360337.html)

Mechanisms of Action: Gene Therapy

Novel Mechanism: No

Modality: Gene Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SNUG-01

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title